Mesalamine Suppository and Sitagliptin Phosphate

• Generic Name: mesalamine
• Dosage Forms: rectal suppository
• Other Brand Names: Apriso, Asacol HD, Delzicol, Lialda, Pentasa, Canasa, Canasa Pac, Rowasa, SfRowasa

Mesalamine affects a substance in the body that causes inflammation, tissue damage, and diarrhea.

Mesalamine is used to treat mild to moderate ulcerative colitis. Mesalamine is also used to prevent the symptoms of ulcerative colitis from recurring.

Some brands of mesalamine are for use only in adults, and some brands are for use in children who are at least 5 years old.

Mesalamine may also be used for purposes not listed in this medication guide.

• Generic Name: sitagliptin
• Dosage Forms: n.a.
• Other Brand Names: Januvia

Used as monotherapy as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.

Used in combination with immediate- or extended-release metformin given separately or as a fixed combination (Janumet or Janumet XR, respectively) as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus when treatment with both sitagliptin and metformin is appropriate.

Used in fixed combination with ertugliflozin (Steglujan) as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus when treatment with both drugs is appropriate.

Used in combination with other oral antidiabetic agents (e.g., metformin, a sulfonylurea, a thiazolidinedione [peroxisome proliferator-activated receptor-γ agonist]) or insulin as an adjunct to diet and exercise in patients with type 2 diabetes mellitus who have not achieved adequate glycemic control with one or more oral antidiabetic agents and/or insulin.

American Association of Clinical Endocrinologists/American College of Endocrinology (AACE/ACE) suggests a DPP-4 inhibitor as one of several alternatives for initial monotherapy in patients with metformin contraindications (e.g., renal disease, hepatic disease, GI intolerance, risk of lactic acidosis). DPP-4 inhibitors also recommended as part of combination therapy, particularly with both postprandial and fasting plasma glucose elevations.

Not indicated for use in patients with type 1 diabetes mellitus or diabetic ketoacidosis; insulin is required in these conditions.